Technology
Lifordi Is Pioneering a Targeted Approach to Enhance Delivery to the Immune System.
Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders.
About
We Are Leading the Way in Developing Novel Treatments for Autoimmune Diseases.
Lifordi is a clinical-stage biotech company developing ADCs that target immune cells to treat autoimmune and inflammatory disorders with precision.
Spotlight
News
Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026
June, 2026